1. Introduction {#sec1}
===============

Pathologically, coronary lesion vulnerability is a key determinant of acute coronary syndrome (ACS) \[[@B1]\]. The potential pathophysiological mechanisms underlying vulnerable plaque rupture include hemodynamic changes, inflammation, oxidative stress, and conventional risk factors for coronary artery disease (CAD), including smoking, obesity, and diabetes \[[@B2], [@B3]\]. However, some healthy individuals who do not present with these risk factors can also develop ACS \[[@B2], [@B3]\]. Therefore, identification of new risk factors to explain individual variation in cardiovascular risk is very important.

Gamma-glutamyl transferase (GGT) is a common enzyme expressed on the cell membrane and distributed in the plasma \[[@B4]\]. GGT is a commonly used indicator of liver function because it is low-cost, highly sensitive, and accurate \[[@B5]\]. Elevated serum GGT levels have been found in patients with hepatobiliary disease and alcohol abuse \[[@B6]\]. Interestingly, some recent studies indicated a potential role of GGT in the diagnosis and prognosis of CAD \[[@B7], [@B8]\]. Moreover, pathological studies demonstrated that GGT was detected in coronary atherosclerotic plaques, suggesting that GGT is involved in CAD pathogenesis \[[@B9]\]. GGT mediates glutathione degradation and leads to the oxidation of low-density lipoprotein cholesterol (LDL-C), which accumulates in the artery wall and causes atherosclerosis \[[@B10]\]. Moreover, GGT located in the atherosclerotic plaque may increase lesion vulnerability by enhancing oxidative stress, cellular apoptosis, plaque rupture, and subsequent thrombosis \[[@B11]\]. Accordingly, previous studies suggested that GGT may serve as a risk marker of cardiovascular diseases, especially CAD \[[@B12], [@B13]\]. Indeed, higher GGT has been associated with CAD incidence \[[@B14], [@B15]\], which can stably persist over time \[[@B16]\]. Similarly, a large-scale cohort study including 163,944 subjects demonstrated that GGT was independently associated with cardiovascular mortality, CAD, congestive heart failure, and ischemic or hemorrhagic stroke during a 17-year follow-up period \[[@B17]\]. Also, each standard deviation increment in log-GGT is associated with a 24% increase in 3-year mortality in ACS patients after percutaneous coronary intervention (PCI) \[[@B18]\]. Furthermore, higher serum GGT levels have been associated with conventional CAD factors, including diabetes, hypertension, and metabolic syndrome \[[@B19]\]. However, evidence is lacking regarding the direct association between serum GGT levels and coronary plaque vulnerability*in vivo*.

Currently, optical coherence tomography (OCT) is the most reliable intraluminal imaging technique for coronary plaque detection and can be used to precisely evaluate coronary lesion vulnerability \[[@B20]\]. To the best of our knowledge, the potential association between serum GGT levels and OCT evidenced coronary vulnerability has not been reported. Therefore, in this study, we investigated if elevated serum GGT levels can predict incidence of plaque vulnerability, defined as plaque rupture or thin-cap fibroatheroma (TCFA) detected by OCT, in CAD patients.

2. Methods {#sec2}
==========

2.1. Patient Selection {#sec2.1}
----------------------

We conducted a single center retrospective cohort study at the First Affiliated Hospital of Xinjiang Medical University. Patients diagnosed with CAD who underwent preintervention OCT examination during coronary angiography (CAG) from January 2015 to October 2018 were included. Patients with the following clinical conditions were excluded: decreased white blood cell counts, decreased platelet counts, autoimmune disease, severe renal dysfunction (serum creatinine ≥ 265 *μ*mol/L or eGFR \< 90 (ml/min/1.73m^2^)), history of hepatitis or positive detection of serum hepatitis B virus antigen, malignant tumors, history of alcohol abuse (defined as alcohol consumption ≥ 100 g/day), and basic liver disease including biliary obstructive disease, acute chronic viral hepatitis, drug-induced hepatitis, and fatty liver that affects GGT levels or alanine aminotransferase (the reference values of our laboratory for serum are 9--50 U/L) more than the triple normal upper limit. All participants provided written informed consent and the study protocol was approved by the ethics committee of the First Affiliated Hospital of Xinjiang Medical University. The flow chart of participant enrollment is shown in [Figure 1](#fig1){ref-type="fig"}.

2.2. Definitions of Cardiovascular Risk Factors {#sec2.2}
-----------------------------------------------

Demographic data, cardiovascular risk factors, and laboratory data were recorded for all patients. Systolic and diastolic blood pressure (SBP and DBP, respectively) were obtained as the average of two physician-obtained measurements using a mercury sphygmomanometer and taken after participants had rested for at least 5 minutes in a sitting position. Hypertension was defined if a patient was actively being treated with antihypertensive drugs or if blood pressure measurements were ≥ 140/90 mmHg on at least three separate occasions \[[@B21]\]. Diabetes mellitus was diagnosed according to the World Health Organization (WHO) criteria or if the patient was using hypoglycemic agents or insulin \[[@B22]\]. The diagnostic criteria for hyperlipidemia were in accordance with the 2016 Chinese Guideline for Prevention and Treatment of Dyslipidemia in Adult Patients \[[@B23]\]. Height and weight were recorded with the participants wearing light clothing and no shoes. Body mass index (BMI) was calculated by dividing the body weight (kg) by the height (m^2^). A BMI \> 28 kg/m^2^ was considered obese \[[@B24]\]. Current smoking was self-reported and was defined as regular cigarette smoking within the prior year. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography within 24 to 48 hours before CAG. We assessed the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Diseases equation \[[@B25]\]. Alcohol consumption was defined as alcohol consumption 50 g/day.

2.3. Measurement of Serum GGT {#sec2.3}
-----------------------------

Blood samples were immediately centrifuged, and plasma and serum specimens were stored at −20°C until assayed. Serum GGT activity was measured using spectrophotometry at 405 nm, which detects the liberation of*p*-nitroaniline, resulting from the reaction of gamma-glutamyl-*p*-nitroanilide + glycylglycine (Quest Diagnostics \[MedPath\]) \[[@B26]\].

2.4. CAG and OCT Analyses {#sec2.4}
-------------------------

CAG was performed using a standard procedure by experienced interventional cardiologists. We used a commercially available C7-XR OCT intravascular imaging system (OCT C7 Dragonfly, St. Jude Medical, St Paul, MN, USA) for OCT analyses. All target lesions before balloon dilatation were examined using standard OCT. The proximal end of the OCT catheter was threaded to the distal end of the lesion, together with the root. The above steps were repeated according to the length of the target vessel and imaging quality, and the positioning of branches or calcification was selected as far as possible. Two or three retractions were performed to complete the target vessel examination, and the distance from the lesion to the opening was determined by two experienced interventionists. Plaque lipid content was semiquantitatively evaluated (angle or quadrant). The thinnest part of the fibrous cap covered by the lipid pool was measured three times, with the average value recorded. Two independent observers performed offline analysis of OCT images in accordance with the established OCT diagnostic criteria to eliminate poor quality images. TCFA was defined as a plaque with a maximal lipid arc \> 90° and thinnest fibrous cap thickness ≤ 65 *μ*m ([Figure 2(a)](#fig2){ref-type="fig"}) \[[@B27], [@B28]\]. Plaque rupture was identified by fibrous cap discontinuity with a cavity formed inside the plaque ([Figure 2(b)](#fig2){ref-type="fig"}) \[[@B27], [@B28]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

All analyses were performed using SPSS 24.0 for Windows statistical software (SPSSInc, Chicago, IL, USA). The sample size of the study was estimated by the following formula: $n = 2\overset{-}{p\,}\overset{-}{q}\left( {u_{a} + u_{\beta}} \right)^{2}/\left( {p_{1} - p_{0}} \right)^{2}$. Continuous variables are expressed as mean ± standard deviation or median (25th to 75th percentiles) values, and categorical variables are presented as percentages. The differences between normally distributed numeric variables were evaluated using one-way ANOVA, and nonnormally distributed variables were analyzed using the Mann--Whitney*U* test or Kruskal--Wallis variance analysis as appropriate. The Chi-square (*χ*2) test was used to compare categorical variables. We classified patients into three groups according to GGT tertiles in the subsequent analyses. To construct the model for multivariate regression analyses, univariate models for each of the predictor variables were run, and the variables that were significant (P \< 0.05) in univariate analysis were entered into multiple linear regression and logistic regression analyses. The odds ratios (OR) and 95% confidence intervals (CIs) were calculated. P \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Characteristics of Patients according to Plaque Vulnerability {#sec3.1}
------------------------------------------------------------------

A total of 142 patients with CAD were included in this study. The baseline characteristics of coronary risk factors and biochemical parameters according to plaque vulnerability as detected by OCT are presented in [Table 1](#tab1){ref-type="table"}. Gender distribution, prevalence of diabetes, levels of Apolipoprotein A1 (ApoA1) and high-density lipoprotein cholesterol (HDL-c), and the proportions of patients with ACS diagnoses were significantly different among the groups. Patients with ruptured plaque or nonrupture with TCFA were more likely to be male, diabetic, dyslipidemic, and diagnosed with ACS compared to those with nonrupture and non-TCFA (P all \< 0.05). GGT plasma levels were not statistically different among the three groups.

3.2. CAG Findings and OCT Analysis {#sec3.2}
----------------------------------

CAG findings and OCT analysis are shown in [Table 2](#tab2){ref-type="table"}. Although the primary CAG findings were not significantly different among the three groups, OCT analysis showed considerable differences in minimal fibrous cap thickness, lipid arc, macrophage accumulation, TCFA, plaque characteristics, and thrombus formation among the three groups (P all \< 0.05).

3.3. Association between Patient Characteristics and Coronary Vulnerability Determined by OCT {#sec3.3}
---------------------------------------------------------------------------------------------

Model 1 indicates the outcome of the plaque rupture group versus the nonplaque rupture with TCFA group, and model 2 indicates the outcome of the nonplaque rupture with TCFA group versus the nonrupture and non-TCFA group. Results of multivariate logistic analyses showed that diabetes (OR: 5.879, P = 0.006) and ACS (OR: 6.876, P = 0.009) were independently associated with plaque rupture and presence of TCFA as determined by OCT ([Table 3](#tab3){ref-type="table"}).

3.4. Relationship of GGT with Patient Characteristics and OCT Findings {#sec3.4}
----------------------------------------------------------------------

Patients were divided into three groups according to tertiles of GGT activity: 1st tertile (GGT \< 23 U/L; n = 48), 2nd tertile (GGT ≥ 23 U/L to 38 U/L; n=47), and 3rd tertile (GGT \> 38 U/L; n = 47). Baseline data in patients with different GGT levels are shown in [Table 4](#tab4){ref-type="table"}. Age, male, oral antidiabetic agents, insulin use, current smoking, current drinking, obesity, levels of triglycerides (TG), alanine aminotransferase (ALT), carbamide, eGFR, unconjugated bilirubin (IBiL), and *β*-blockers were significantly different across the GGT tertiles (all P \< 0.05). Incident of proximal target plaque in the 1st tertile was higher compared to the 2nt tertile combined with the 3rd tertile (P = 0.014). Moreover, OCT findings in patients among the three groups with different levels of GGT were not significantly different ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

In this study, we found that circulating GGT levels were not associated with an increased risk of coronary lesion vulnerability, as indexed by TCFA and plaque rupture using OCT analysis, in patients with CAD. The pathophysiological mechanisms underlying the potential association between GGT and CAD incidence and prognosis may not have previously included contribution of GGT to plaque vulnerability.

Previous studies reported an association between GGT and CAD risk and prognosis. A prospective study including 469 patients with ischemic syndrome and CAG documented CAD confirmed that GGT activity is an independent prognostic marker of incidence of cardiac death and infarction \[[@B29]\]. In addition, a positive and independent correlation between baseline levels of GGT and risk of sudden cardiac death in the general male population was confirmed in a cohort study with a 22-year follow-up \[[@B30]\]. Moreover, high serum GGT levels have been independently and significantly correlated with coronary artery calcification score progression in an asymptomatic middle-aged population \[[@B31]\]. However, these studies focused on the association between GGT and CAD incidence and prognosis, rather than the potential association between GGT and coronary lesion characteristics, which previously limited our understanding of the insights into the potential association between GGT and coronary atherosclerotic plaque vulnerability. Our study used OCT, referred to as a histologic microscope*in vivo* \[[@B32]\], and showed that higher GGT levels were not associated with plaque vulnerability. Interestingly, several studies revealed that elevated GGT in CAD patients may be explained by alcohol consumption but that light to moderate alcohol drinking may have a protective effect against CAD and myocardial infarction \[[@B33]--[@B35]\]. However, these hypotheses are challenged by recent findings that do not support a protective effect of alcohol consumption \[[@B36], [@B37]\]. Therefore, the potential mechanisms underlying the association between GGT and CAD require further investigation. However, previous studies have provided some insight into the potential mechanisms underlying the association between GGT and CAD. GGT is the hydrolytic enzyme of extracellular glutathione (GSH), a main antioxidant factor*in vivo*\[[@B4]\]. By hydrolyzing GSH, GGT causes an imbalance of LDL oxidation and leads to overproduction of oxidized LDL (ox-LDL), a key component of atherosclerotic plaques \[[@B38]\]. Therefore, GGT may directly participate in the development of atherosclerosis by mediating the oxidative stress response \[[@B39], [@B40]\]. Thus, GGT may be involved in the pathogenesis of atherosclerotic plaque formation, but not plaque vulnerability.

Numerous clinical epidemiological studies have suggested that elevated GGT levels are not only related to liver diseases and alcohol consumption but also closely related to the incidence and development of many systemic diseases, such as hypertension, serum hyperlipemia, diabetes, and metabolic syndrome \[[@B4], [@B17], [@B41], [@B42]\]. GGT might be a potentially reliable, simple, and noninvasive biochemical marker for determining cardiovascular risk, which may be helpful for successful disease prognosis. However, further studies including larger populations are necessary to confirm this conclusion. Consistent with previous studies, our univariate analysis showed that age, male, oral antidiabetic agents, insulin use, current smoking, current drinking, obesity, and increased TG were significantly different when considering GGT levels. These results also confirmed that circulating GGT may be closely correlated with conventional risk factors for CAD incidence, rather than plaque vulnerability.

4.1. Study Limitations {#sec4.1}
----------------------

Our study has several limitations. First, depth of OCT does not permit us to assess plaque volume or positive remodeling of atheromatous plaques. Secondly, we only analyzed plaque composition at the site of target lesions; thus, the association between diabetes, obesity, and coronary vulnerability in nontarget lesions should also be determined in future studies. Thirdly, we only collected baseline GGT data during the study duration. Therefore, the effect of dynamic changes of GGT on plaque vulnerability could not be determined. Fourth, no inflammatory markers, such as high-sensitive C reactive protein and ox-LDL, were assessed in this study, and these factors may confound the results. Finally, this was a single center retrospective study, and our results need to be further verified with a multicenter, prospective study.

5. Conclusions {#sec5}
==============

Serum GGT was not associated with coronary vulnerability as determined by OCT in our cohort. The pathophysiological mechanisms underlying the potential association between GGT and CAD incidence and prognosis as observed in previous clinical studies may not include contribution of*circulating GGT* levels to plaque vulnerability.
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###### 

Characteristics of patients according to plaque vulnerability.

                                   Ruptured plaque   Nonrupture with TCFA   Nonrupture and non-TCFA   t/Z/*χ*^2^   P
  -------------------------------- ----------------- ---------------------- ------------------------- ------------ ---------
  Sex (Male/Female)                15/1              15/2                   74/35                     8.331        0.016
  Age                              59.63±10.15       54.65±9.23             56.89±11.99               0.773        0.463
  Hypertension                     10 (62.5)         9 (52.9)               57 (52.3)                 0.587        0.746
  Diabetes mellitus                10 (62.5)         10 (58.8)              25 (22.9)                 16.657       \<0.001
  DM treatment                                                                                                      
   Oral hypoglycemic drugs         6 (37.5)          2 (11.8)               16 (14.7)                 4.614        0.100
   Insulin                         3 (18.8)          0 (0.0)                13 (11.9)                 4.876        0.087
   Diet only                       0 (0.0)           0 (0.0)                4 (3.7)                   2.168        0.338
  Current smoking                  9 (56.3)          9 (52.9)               60 (55.0)                 0.039        0.981
  Alcohol drinking                 4 (25.0)          2 (11.8)               19 (17.4)                 0.993        0.609
  Family history of CAD            2 (12.5)          1 (5.9)                24 (22.0)                 3.566        0.168
  Previous myocardial infarction   1 (6.3)           3 (17.6)               21 (19.3)                 2.004        0.367
  Previous PCI                     2 (12.5)          2 (11.8)               31 (28.4)                 4.063        0.131
  SBP (mmHg)                       129.38±26.20      125.65±17.16           124.84±17.87              0.403        0.669
  DBP (mmHg)                       74.25±23.31       73.29±8.04             76.03±12.12               0.383        0.683
  Obesity (BMI≥28kg/m^2^)          7 (43.8)          6 (35.3)               35 (32.1)                 0.864        0.649
  HDL-C (mmol/l)                   0.83±0.15         0.89±0.09              1.07±0.30                 7.380        0.001
  LDL-C (mmol/l)                   2.39±0.87         2.60±0.69              2.30±0.90                 0.824        0.441
  TC (mmol/l)                      3.61±0.98         4.09±0.72              3.67±1.08                 1.251        0.290
  TG (mmol/l)                      1.94±0.84         1.90±0.77              1.82±0.96                 0.136        0.873
  ApoA1 (g/L)                      0.96±0.13         1.01±0.08              1.15±0.25                 7.171        0.001
  ApoB (g/L)                       0.78±0.28         0.87±0.21              0.8±0.54                  0.165        0.848
  Lp (a) (g/L)                     219 (147,358)     147 (57,326)           182 (96,386)              2.691        0.260
  HbA1c (%)                        7.07±1.34         5.96±0.36              6.36±1.33                 1.586        0.212
  ALT (U/L)                        35.64±21.54       31.86±21.61            31.89±24.33               0.178        0.837
  AST (U/L)                        25.31±12.09       20.07±6.34             30.46±36.99               0.825        0.440
  Creatinine (*μ*mmol/L)           77.54±17.24       74.3±16.51             74.15±19.72               0.221        0.802
  BUN (mmol/l)                     5.96±1.85         5.01±1.52              5.54±1.6                  1.430        0.243
  eGFR (ml/min/1.73m^2^)           110.28±47.59      107.07±29.18           106.76±37.72              0.060        0.942
  Uric acid (*μ*mol/L)             356.47±72.48      338.83±79.78           331.33±99.4               0.506        0.604
  TBil (mmol/l)                    12.1±3.95         13.88±4.76             13.46±10.47               0.174        0.840
  DBiL (mmol/l)                    3.04±1.38         3.57±1.41              3.71±2.78                 0.493        0.612
  IBiL (mmol/l)                    9.16±3.93         10.31±4.63             9.38±5.91                 0.231        0.794
  EF (%)                           61.34±7.02        60.38±10.15            61.25±6.85                0.097        0.908
  GGT (U/L)                        25 (18,40)        32, (19,65)            28 (20,43)                1.708        0.426
  GGT tertiles                                                                                        2.843        0.584
   1st tertile                     6 (37.5)          6 (35.3)               35 (32.1)                               
   2st tertile                     6 (37.5)          3 (17.6)               38 (34.9)                               
   3st tertile                     4 (25.0)          8 (47.1)               36 (33.0)                               
  ALP                              74.74±20.43       79.45±24.98            78.07±23.09               0.192        0.826
  ACS                              13 (81.3)         13 (76.5)              47 (43.1)                 12.977       0.002
  Aspirin                          11 (68.8)         14 (82.4)              85 (78.0)                 0.907        0.635
  Statins                          11 (68.8)         12 (70.6)              82 (75.2)                 0.407        0.816
  *β*-Blockers                     7 (43.8)          3 (17.6)               43 (39.4)                 3.307        0.191
  ACEI/ARB                         6 (37.5)          6 (35.3)               41 (37.6)                 0.034        0.983
  CCB                              5 (31.3)          5 (29.4)               27 (24.8)                 0.407        0.816
  GRACE risk score                 102.33±17.76      108.11±26.35           108.36±28.64              0.190        0.828

Data are presented as n (%) or mean ± SD.

BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TBil, total bilirubin; DBiL, direct bilirubin; IBiL, unconjugated bilirubin; Apo A1, Apo lipoprotein AI; Apo B, Apo lipoprotein B; Lp (a), lipoprotein (a); SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.

###### 

CAG findings and OCT characteristics according to plaque vulnerability.

                                            Ruptured plaque   Non-rupture with TCFA   Non-rupture and non-TCFA   t/*χ*^2^   P
  ---------------------------- ------------ ----------------- ----------------------- -------------------------- ---------- ---------
  Erosion (%)                  No           14 (87.5)         12 (70.6)               97 (89.0)                  3.533      0.171
                               Yes          2 (12.5)          5 (29.4)                12 (11.0)                              
  Macrophage accumulation      0            3 (18.8)          4 (23.5)                69 (63.3)                  28.094     \<0.001
  1                            6 (43.8)     7 (41.2)          25 (22.9)                                                     
                               2            5 (37.5)          5 (29.4)                15 (13.8)                              
                               3            1 (6.3)           1 (5.9)                 0 (0.0)                                
                               4            1 (6.3)           0 (0.0)                 0 (0.0)                                
  Vasa vasorum                 No           15 (93.8)         14 (82.4)               102 (93.6)                 2.098      0.350
                               Yes          1 (6.3)           3 (17.6)                7 (6.4)                                
   Thrombus                    No           4 (25.0)          10 (58.8)               97 (89.0)                  32.340     \<0.001
                               Yes          12 (75.0)         7 (41.2)                12 (11.0)                              
  Calcified nodule             No           16 (100.0)        17 (100.0)              101 (92.7)                 4.374      0.112
  Yes                          0 (0.0)      0 (0.0)           8 (7.3)                                                       
  Characteristic of plaque     Lipid        15 (93.7)         17 (100.0)              64 (58.7)                  25.106     \<0.001
  Calcified                    1 (6.3)      0 (0.0)           21 (19.3)                                                     
                               Fibrotic     0 (0.0)           0 (0.0)                 24 (22.0)                              
  Minimal lumen area (mm^2^)                3.46±1.89         3.72±1.95               3.34±1.88                  0.258      0.773
  Normal lumen area (mm^2^)                 13.04±2.77        11.03±2.75              10.08±3.13                 5.245      0.007
  Diameter stenosis, %                      83.69±12.23       73.24±14.36             76.85±12.76                2.867      0.060
  Lesion length                             9.54±4.18         9.73±2.94               10.22±3.5                  0.355      0.702
  Target vessel                LAD, n (%)   10 (62.5)         12 (70.6)               85 (78.0)                  4.125      0.389
                               LCX, n (%)   2 (12.5)          3 (17.6)                6 (5.5)                                
                               RCA, n (%)   4 (25.0)          2 (11.8)                18 (16.5)                              
  Location of target plaque    Proximal     10 (62.5)         12 (70.6)               72 (66.1)                  0.245      0.885
  Mid-Distal                   6 (37.5)     5 (29.4)          37 (33.9)                                                     
  TIMI classification          0            1 (6.3)           1 (5.9)                 1 (0.9)                    9.933      0.077
  1                            0 (0.0)      0 (0.0)           2 (1.8)                                                       
                               2            2 (12.5)          3 (17.6)                5 (4.6)                                
                               3            13 (81.3)         13 (76.5)               101 (92.7)                             
  Number of vascular lesions   1            8 (50.0)          8 (47.1)                52 (47.7)                  0.833      0.934
  2                            5 (31.3)     4 (23.5)          34 (31.2)                                                     
  3                            3 (18.8)     5 (29.4)          23 (21.1)                                                     

###### 

Predictors of plaque vulnerability as detected by ruptured plaque or non-rupture with TCFA: multivariate logistic regression analysis.

             Model 1   Model 2                                  
  ---------- --------- --------- -------------- ------- ------- --------------
  HDL-c      0.210     0.064     0.001-4.672    0.569   0.347   0.009-13.162
  ApoA1      0.403     0.136     0.001-14.645   0.438   0.182   0.002-13.502
  Diabetes   0.006     5.879     1.651-20.939   0.005   5.395   1.657-17.567
  ACS        0.009     6.876     1.620-29.189   0.013   5.115   1.419-18.431
  Sex        0.075     7.605     0.818-70.682   0.119   3.756   0.711-19.849

OR, odds ratio; CI, confidence interval.

###### 

Characteristics of participants according to serum GGT tertiles.

                                   1st tertile    2nd tertile    3rd tertile     t/Z/*χ*^2^   P
  -------------------------------- -------------- -------------- --------------- ------------ ---------
  Sex (Male/Female)                24/23          36/11          44/4            20.379       \<0.001
  Age                              60.26±10.69    58.15±10.29    52.48±12.17     6.265        0.002
  Hypertension                     20 (42.6)      29 (61.7)      27 (56.3)       3.681        0.159
  Diabetes mellitus                13 (27.7)      15 (31.9)      17 (35.4)       0.662        0.718
  DM control                                                                                   
   Oral hypoglycemic agents        4 (8.5)        13 (27.7)      7 (14.6)        6.413        0.041
   Insulin                         4 (8.5)        10 (21.3)      2 (4.2)         7.488        0.024
   Diet only                       0 (0.0)        1 (2.2)        3 (6.3)         4.306        0.116
  Current smoking                  15 (31.9)      27 (57.4)      36 (75.0)       17.986       \<0.001
  Alcohol drinking                 4 (8.5)        6 (12.8)       15 (31.3)       9.599        0.008
  Family history of CAD            7 (14.9)       8 (17.0)       12 (25.0)       1.756        0.416
  Previous myocardial infarction   12 (25.5)      4 (8.5)        9 (18.8)        4.759        0.093
  Previous PCI                     14 (29.8)      10 (21.3)      11 (22.9)       1.033        0.596
  SBP (mmHg)                       124.36±20.59   127.85±18.80   124.17±17.03    0.571        0.566
  DBP (mmHg)                       74.13±12.88    76.45±12.82    75.92±14.49     0.386        0.681
  Obesity (BMI≥28kg/m^2^)          9 (19.1)       17 (36.2)      22 (45.8)       7.733        0.021
  HDL-c (mmol/l)                   1.03±0.26      1.07±0.32      0.96±0.27       1.788        0.171
  LDL-c (mmol/l)                   2.26±0.74      2.36±0.82      2.42±1.04       0.381        0.684
  TC (mmol/l)                      3.55±0.91      3.74±1.05      3.85±1.15       0.957        0.387
  TG (mmol/l)                      1.55±0.77      1.79±0.83      2.20±1.04       6.564        0.002
  ApoA1 (g/L)                      1.12±0.23      1.14±0.24      1.08±0.23       0.712        0.493
  ApoB (g/L)                       0.76±0.22      0.86±0.76      0.8±0.31        0.467        0.628
  Lp (a) (g/L)                     205 (76,353)   174 (97,404)   184 (119,347)   0.522        0.770
  HbA1c (%)                        6.03±1.05      6.67±1.52      6.48±1.21       1.443        0.243
  ALT                              22.52±12.5     30.56±24.57    43.59±26.43     11.021       \<0.001
  AST                              23.66±14.85    30.1±43.46     32.07±33.76     0.846        0.431
   Creatinine                      73.84±21.96    74.71±17.96    75.09±17.22     0.054        0.948
  BUN                              5.25±1.49      6.01±1.65      5.3±1.65        3.329        0.039
  eGFR                             95.15±28.33    108.39±39.75   117.81±41.14    4.519        0.013
  Uric Acid (*μ*mol/L)             315.75±91.44   343.14±92.4    346.07±98.19    1.492        0.228
  TBil (mmol/l)                    12.05±4.91     12.08±4.53     15.88±14.55     2.677        0.072
  DBiL (mmol/l)                    3.75±2.13      3.13±1.52      3.96±3.47       1.411        0.247
  IBiL (mmol/l)                    8.31±3.99      8.98±3.94      11.09±7.6       3.346        0.038
  EF (%)                           61.35±6.81     61.8±4.43      60.37±9.54      0.455        0.635
  ALP                              71.85±16.37    78.40±26.66    83.22±23.50     3.027        0.052
  ACS                              26 (55.3)      25 (53.2)      22 (45.8)       0.945        0.624
  Aspirin                          33 (70.2)      36 (76.6)      41 (85.4)       3.175        0.204
  Statins                          30 (63.8)      35 (74.5)      40 (83.3)       4.698        0.095
  *β*-Blockers                     12 (25.5)      17 (36.2)      24 (50.0)       6.117        0.047
  ACEI/ARB                         14 (29.8)      16 (34.0)      23 (47.9)       3.660        0.160
  CCB                              12 (25.5)      14 (29.8)      11 (22.9)       0.592        0.744
  GRACE risk score                 103.40±32.72   112.56±20.21   105.65±28.69    0.757        0.473

Abbreviations are the same as those in [Table 1](#tab1){ref-type="table"}.

###### 

CAG findings and OCT analysis in patients according to the three groups.

                               Group        1st tertile    2nd tertile    3rd tertile    t/Z/*χ*^2^   P
  ---------------------------- ------------ -------------- -------------- -------------- ------------ -------
  FCT (*μ*m)                                100 (40,200)   140 (60,200)   140 (60,220)   2.877        0.237
  Lipid arc, degree                         100 (0,165)    114 (0,180)    147 (15,202)   3.321        0.190
  Rupture (%)                  No           41 (87.2)      41 (87.2)      44 (91.7)      0.624        0.732
                               Yes          6 (12.8)       6 (12.8)       4 (8.3)                      
  Erosion (%)                  No           40 (85.1)      40 (85.1)      43 (89.6)      0.549        0.760
                               Yes          7 (14.9)       7 (14.9)       5 (10.4)                     
  Macrophage accumulation      0            28 (59.6)      24 (51.1)      24 (50.0)      4.465        0.910
  1                            10 (21.3)    14 (29.8)      14 (29.2)                                  
                               2            8 (17.0)       8 (17.0)       9 (18.8)                     
                               3            1 (2.1)        1 (2.1)        0 (0.0)                      
                               4            0 (0.0)        1 (2.1)        1 (2.1)                      
  Vasa vasorum                 No           44 (93.6)      45 (95.7)      42 (87.5)      2.374        0.305
                               Yes          3 (6.4)        2 (4.3)        6 (12.5)                     
   Thrombus                    No           37 (78.7)      37 (78.7)      37 (77.1)      0.050        0.975
                               Yes          10 (21.3)      10 (21.3)      11 (22.9)                    
  Calcified nodule             No           45 (95.7)      43 (91.5)      46 (95.8)      1.033        0.597
  Yes                          2 (4.3)      4 (8.5)        2 (4.2)                                    
  Characteristic of plaque     Lipid        30 (63.8)      30 (63.8)      36 (75.0)      4.863        0.302
  Calcified                    10 (21.3)    9 (19.1)       3 (6.3)                                    
                               Fibrotic     7 (14.9)       8 (17.0)       9 (18.8)                     
  TCFA                         No           36 (76.6)      39 (83.0)      37 (77.1)      0.714        0.700
                               Yes          11 (23.4)      8 (17.0)       11 (22.9)                    
  Minimal lumen area (mm^2^)                3.79±2.42      3.41±1.66      3.09±1.54      1.312        0.273
  Normal lumen area (mm^2^)                 10.9±3.74      10.91±2.94     9.8±2.79       1.688        0.189
  Diameter stenosis, %                      75.53±11.9     79.15±13.41    76.9±13.82     0.918        0.402
  Lesion Length                             9.84±3.72      10.35±3.53     10.05±3.32     0.255        0.775
  Target vessel                LAD, n (%)   39 (83.0)      34 (72.3)      34 (70.8)      5.400        0.249
                               LCX, n (%)   4 (8.5)        2 (4.3)        5 (10.4)                     
                               RCA, n (%)   4 (8.5)        11 (23.4)      9 (18.8)                     
  Location of target plaque    Proximal     35 (74.5)      35 (74.5)      24 (50.0)      8.501        0.014
  Mid-Distal                   12 (25.5)    12 (25.5)      24 (50.0)                                  
  TIMI classification          0            0 (0.0)        2 (4.3)        1 (2.1)        4.433        0.673
  1                            1 (2.1)      0 (0.0)        1 (2.1)                                    
                               2            5 (10.6)       2 (4.3)        3 (6.3)                      
                               3            41 (87.2)      43 (91.5)      43 (89.6)                    
  Number of vascular lesions   1            21 (44.7)      20 (42.6)      27 (56.3)      3.722        0.445
  2                            13 (27.7)    18 (38.3)      12 (25.0)                                  
  3                            13 (27.7)    9 (19.1)       9 (18.8)                                   

Abbreviations are the same as those in [Table 1](#tab1){ref-type="table"}.

[^1]: Academic Editor: Antonello Merlino
